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Synthesis of the Floxuridine oligonucleotide (oligo-FdU)
Two pentanucleotide sequences were prepared: 1) 5'-(FdU) 5 -3' is the control FdU pentamer:
and 2) 3'-thiolated FdU pentamer: 5'-(FdU) 5 -HEG-propyl-SH 3' with FdU 5-fluoro-2'-deoxyuridine and HEG as hexaethylenegycol spacer.
To synthetize the control 5'-(FdU) 5 -3' pentamer, we used a controlled pore glass (CPG) support functionalized with DMT-FdU prepared as described above. Then, the control pentamer sequence was assembled on a DNA synthesizer (392 Applied Biosystems, Foster City, CA, USA) using a 1 µmol synthesis cycle by successive additions of DMT-protected FdU phosphoramidite. After assembling of the sequence, oligonucleotide support was treated with aqueous ammonia (32%) for 2 hrs at room temperature and the resulting product was purified by HPLC. HPLC conditions: column X-bridgeTM OST C18 (10x50 mm, 2.5 µm); 20 min linear gradient from 0 % to 40%, flow rate 2 mL/min; solution A was 5% acetonitrile in 0.1 M aqueous triethylammonium acetate(TEAA) and solution B 70% acetonitrile in 0.1 M aqueous TEAA. Pentamer was characterized by mass spectrometry (MALDI-TOF).
Several batches of pentamer FdU oligonucleotide were synthesized in 1 µmol scale on an automated RNA/DNA synthesizer using β-cyanoethylphosphoramidite chemistry and following standard protocols. 3'-Thiol-Modifier C3 solid support (Link Technologies, Lanarkshire, Scotland) was used for the introduction of the thiol group at the 3'-end, then hexaethyleneglycol phosphoramidite (Glen Research) was used as spacer. Finally, the synthesis was completed by repetitive additions of the DMT-protected FdU phosphoramidite. After the assembly of the sequence, oligonucleotide support was treated with aqueous ammonia (32%) with 0.1 M 1,4-dithiothreitol (DTT) for 2h at room temperature. The ammonia solution was concentrated to dryness and the product was desalted on NAP-10 (Sephadex G-25) columns eluted with water prior to use. The purity of the pentamer FdU-HEG-SH was analyzed by HPLC using the conditions described above (see appendix Fig. S1 ).
Pentamer was quantified by absorption at 260 nm and confirmed by MALDI mass spectrometry (MALDI-TOF).
Characterization
of the T22-GFP-H6-FdU therapeutic nanoconjugate and determination of Drug/Nanoparticle Ratio
The products obtained after the T22-GFP-H6-FdU synthesis reaction were characterized using mass spectroscopy to measure their molecular mass. The volume and size distribution of the nanoparticles was determined by dynamic light scattering at 633 nm (Zetasizer Nano ZS, Malvern
Instruments Limited, Malvern, Worcestershire, UK). Nanoconjugate size was also measured using purified samples, diluted to 0.2 mg/mL and contrasted by evaporation of 1 nm platinum layer in carbon-coated grids, before being visualized in a Hitachi H-7000 transmission electron microscope (TEM), as described (Unzueta 2012b). The drug to nanoparticle ratio was obtained by analyzing the UV spectra of T22-GFP-H6 and T22-GFP-H6-FdU nanoconjugate and calculating the number of FdU molecules per T22-GFP-H6 nanoparticle.
T22-GFP-H6-FdU internalization, CXCR4 specificity and cytotoxicity in CXCR4 + HeLa cells
We assessed T22-GFP-H6-FdU capacity to internalize in a second cell type, the CXCR4 (Protein:antagonist) molar ratio for 1h before exposure to the nanoconjugate, as previously described for the T22-GFP-H6.
We assessed T22-GFP-H6-FdU subcellular localization using confocal microscopy. Briefly, cells were grown on culture dishes (Mat-Tek Co., Ashland, MA, USA); then, T22-GFP-H6-FdU was added in OptiPro medium supplemented with L-Glutamine. Nuclei were labeled with Hoechst 33342
(Life Technologies, Carlsbad, CA, USA) and plasma membranes with CellMaskTM Deep Red (Life Technologies) as described (Unzueta et al, 2012b) . Micrographs were taken by TCS-SP5 confocal laser scanning microscopy (Leica Microsystems Wetzlar,Germany) and 3D models of T22-GFP-H6-FdU localization were generated using Imaris software (Bitplane, Zurich, Switzerland).
We also studied T22-GFP-H6-FdU cytotoxic activity using the MTT metabolic test (Roche, Basel, Switzerland). To that purpose, we exposed CXCR4 + HeLa cells to T22-GFP-H6-FdU at 1-1,000nM
concentration range and measured their viability at 48 hours as compared to equimolecular concentrations or free oligo-FdU. Afterwards, we constructed a graphic displaying the linearized T22-GFP-H6-FdU dose-response trend line representation to compare cell viability for both compounds.
Reduction of cell viability was also determined by optical microscope images of HeLa cells exposed to 1µM T22-GFP-H6-FdU for 48 h, as compared to T22-GFP-H6 or free FdU. were sacrificed by cervical dislocation and tumours were excised, discarding the necrotic areas, and three hundred mg of viable tumour tissue was then cut into pieces and disaggregated in a mix of 0.05% trypsin (Invitrogen) and 100 mg/ml DNase (Sigma-Aldrich). The mix was pipetted 30 times, using a 10 ml pipette, and incubated for 10 minutes at 37°C with shaking. It was then re-pipetted 30 times, using 10 ml, 3 ml and 1 ml pipettes, and re-incubated for 5 minutes at 37°C with shaking. The obtained SW1417 single-cell suspensions were filtered through a cell strainer and centrifuged at 1,000g for 10 minutes before counting the cells. We then microinjected 2×10 6 cells, previously grown in culture and resuspended in 50 µl of media, in the cecum of each mouse.
T22-GFP-H6-FdU induction of
We used the SC+ORT metastatic SW1417 CRC model developed in NOD/SCID to evaluate the capacity of the nanoconjugate for metastasis prevention. We ramdomized mice into three groups:
buffer (n=11), T22-GFP-H6-FdU (n=12) and free oligo-FdU (n=11) and administered repeated i.v.
boluses at equimolecular doses, as follows: T22-GFP-H6-FdU 20ug, free oligo-FdU: 2.6 nmols, or buffer), every three days (q3d) for a total of 12 doses. We initiated the T22-GFP-H6-FdU administration one week after tumor cell implantation before metastatic dissemination had occurred (Appendix Fig S5) . The experiment was finished when the first animal of the Buffer-treated group required to be euthanized. At necropsy, we recorded the number and size of visible metastases in all organs per mouse, counted ex vivo the number of metastatic foci that emitted bioluminiscence in the target organs, using the IVIS® 200-Spectrum, and performed the histopathological and immunohistochemical analyses to confirm location and number of metastases. We also evaluated CXCR4 expression by IHC, using the described anti-CXCR4 antibody, in primary tumor and metastatic foci at the different organs affected by metastases (peritoneum, liver, lung and lymph nodes). We quantified the fraction of CXCR4 + cancer cells remaining in tumor tissue (CXCR4 + CCF) after 6 treatment. The obtained results were used to study a possible correlation between CXCR4 + CCF and antimetastatic effect at the different sites.
T22-GFP-H6-FdU biodistribution and toxicity in bone marrow and circulating blood cells
We used mice bearing subcutaneous CXCR4 + SW1417 CRC tumors to assess T22-GFP-H6-FdU uptake (measuring green fluorescence emission) in bone marrow and circulating blood cells 5h
after the administration of T22-GFP-H6-FdU at a range of 10-100 µg doses. At necropsy, bone marrow was extracted and registered ex vivo in the IVIS® 200-Spectrum equipment. Mouse blood was collected by punction in the maxillary plexus. The erythrocytes, leucocytes and platelets were isolated by the Ficoll density gradient method using the standard protocol. Further, pellets were obtained by centrifugation of the isolated cell extracts at 600g, 10min and then recorded to measure fluorescence using IVIS® 200-Spectrum equipment. Toxicity was evaluated in H&E stained bone marrow slides.
Statistical analysis
Sample size was defined on the basis of previous preliminary experiments. No animals nor samples were excluded from the analyses. Randomization of animals into control and experimental groups were performed using the SPSS program. Histology and immunohistochemical samples were coded so that the researcher that analysed them did not know to which group they belong to. Normal distribution of the data was tested using the Shapiro-wilk test. The homeogeneity of the variance between groups was tested using the Levene´s test. We used the Fisher's exact test to analyze possible differences between control and experimental groups of affected mice regarding metastatic rates at the different organs. The non-parametric tests, Kruskal-Wallis and post-hoc pairwise Mann-Whitney U two-sided tests were used to compare number and size of metastatic foci in the affected organs among groups. All quantitative values were expressed as mean±s.e.m. All statistical tests were performed using SPSS version 11.0 (IBM, New York, USA). Differences among groups was considered significant at a P <0.05.
Appendix Table S1 . Number of mice with undetectable metastases (Mets-free) and number of mice bearing metastatic foci (Mets +) at the end of the prevention of metastasis experiment in the T22-GFP-H6-FdU, free oligo-FdU or Buffer-treated groups, when using both, the sw1417 or M5 colorectal metastatic models. Free oligo-FdU; T-F: T22-GFP-H6-FdU).
Appendix
-ɣ-H2AX quantification between groups at specific time points: P values for Statistical Differences: Note that representative microphotographs of tumor cells IHC-stained for anti-γH2AX 5h after treatment with T22-GFP-H6-FdU, free oligo-FdU or Buffer are depicted in Figure 3A of the main text.
